48
Participants
Start Date
October 30, 2025
Primary Completion Date
January 30, 2028
Study Completion Date
January 1, 2029
177Lu-PSMA-617
Administeration by intravenous infusion or injection at an activity of 7.4 GBq every 6 weeks (±1 week) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity or until the occurrence of a withdrawal criterion. The first infusion should be administered within 3 weeks from enrolment. Patients in PR or SD after 4 cycles will receive an additional two doses.
Collaborators (1)
Advanced Accelerator Applications
INDUSTRY
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK